查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球非轉移性前列腺癌市場：區域與國家分析與預測（2025-2035）
市場調查報告書
商品編碼
1764708

全球非轉移性前列腺癌市場：區域與國家分析與預測（2025-2035）

Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

非轉移性前列腺癌市場的主要成長要素之一是對分子標靶治療的需求不斷增加，尤其是針對非轉移性去勢抗性前列腺癌 (nmCRPC)。

隨著前列腺癌的進展，需要更有效、更個人化的治療方法，尤其是對於那些對雄性激素剝奪療法 (ADT) 等標準荷爾蒙療法有抗藥性的高風險患者。由於Enzalutamide(Xtandi) 和阿帕魯胺 (Erleada) 等雄性激素受體抑制劑在延緩轉移和提高存活率方面的成功，對此類治療的需求激增。

此外，PSA檢測和多參數MRI等早期診斷技術的進步，以及人們對攝護腺癌認知的提高，有助於早期發現非轉移性攝護腺癌。早期診斷使我們能夠迅速啟動創新治療，從而刺激了治療需求的成長。基於基因檢測和生物標記的精準醫療的廣泛應用，也使得每位患者都能獲得個人化治療，進一步加速了市場的成長。

總體而言，對更先進、毒性更小、更有效的治療方法、早期發現和意識提升的需求正在強力推動非轉移性前列腺癌市場的擴張。

然而，市場發展仍面臨諸多挑戰。其中一個主要挑戰是先進治療方法的高成本。雄激素受體抑制劑（例如Enzalutamide和阿帕魯胺）以及免疫療法和分子標靶療法等較新的治療方法價格昂貴，對於沒有全面保險的患者來說難以獲得。這些昂貴的療法也給整個醫療保健系統帶來了沉重的財務負擔，使其難以推廣應用，尤其是在醫療資源有限的開發中國家。

除了成本障礙外，另一個重大挑戰是抗治療性。儘管Enzalutamide和阿帕魯胺等藥物已顯示出對非轉移性去勢抗性前列腺癌 (nmCRPC) 的高效治療，但許多患者在長期使用後會產生抗藥性。抗藥性會增加癌症進展的風險，迫使醫生考慮替代療法和更具侵入性的干涉措施。然而，這些替代療法並非總是有效，在某些情況下，選擇有限。儘管持續進行去勢治療，去勢抗性仍然是前列腺癌長期治療中最嚴峻的挑戰之一。

此外，診斷技術也存在限制。儘管多參數磁振造影（MRI）和基因檢測等技術取得了進步，但前列腺癌的早期階段仍然難以檢測。此外，廣泛使用的PSA檢測特異性有限，並且可能產生假陽性和假陰性。這可能導致誤診或延誤診斷，從而阻礙制定合適的治療方案。

最後，目前治療方法（尤其是雄性激素剝奪療法和化療）的副作用持續顯著影響患者的生活品質。疲勞、性功能障礙、骨質疏鬆症和心血管風險等問題使許多患者難以接受長期治療，並可能導致治療依從性不佳，進一步加劇了非轉移性前列腺癌的治療難度。

本報告調查了全球非轉移性前列腺癌市場，並總結了主要趨勢、市場影響因素分析、法律制度、技術和專利分析、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章全球非轉移性前列腺癌市場：產業展望

  • 市場趨勢
  • 法律規範
  • 流行病學分析
  • 臨床試驗分析
  • 市場動態
    • 影響分析
    • 市場促進因素
    • 市場挑戰
    • 市場機會

2. 全球非轉移性前列腺癌市場（按地區）

  • 北美洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 歐洲
    • 主要發現
    • 市場動態
    • 市場規模及預測
  • 亞太地區
    • 主要發現
    • 市場動態
    • 市場規模及預測

3. 全球非轉移性前列腺癌市場：競爭格局與公司概況

  • 關鍵策略和發展
    • M&A
    • 協同活動
    • 業務擴展和資金籌措
    • 產品發布和核准
    • 其他活動
  • 公司簡介
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Astellas Pharma
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Merck & Co.
    • Bayer AG
    • Sanofi
    • Clovis Oncology
    • AstraZeneca
    • AbbVie Inc.

第4章調查方法

Product Code: BHL3085SA

Global Non-metastatic Prostate Cancer Market, Analysis and Forecast: 2025-2035

Non-metastatic prostate cancer refers to a stage of prostate cancer where the disease remains confined to the prostate gland and has not spread to other parts of the body. This form of cancer is often diagnosed at an early stage through methods such as prostate-specific antigen (PSA) testing, digital rectal exams (DRE), and biopsy. Non-metastatic prostate cancer is typically classified as Stage I or Stage II in the TNM (Tumor, Node, Metastasis) staging system, where the tumor is localized within the prostate and there is no evidence of spread to nearby lymph nodes or distant organs. While the cancer may cause a slight or moderate rise in PSA levels, it is often still manageable with localized treatments. Common treatment options include active surveillance for less aggressive cases, radical prostatectomy (surgical removal of the prostate), or radiation therapy. In high-risk cases, androgen deprivation therapy (ADT) may be used to lower testosterone levels and prevent cancer progression. With early detection and appropriate treatment, non-metastatic prostate cancer generally has a favorable prognosis, but management varies depending on factors such as cancer aggressiveness, patient age, and overall health.

One of the key drivers of the Non-metastatic Prostate Cancer market is the increasing demand for targeted therapies, particularly for non-metastatic castration-resistant prostate cancer (nmCRPC). As prostate cancer evolves, particularly in high-risk patients who develop resistance to standard hormonal therapies like androgen deprivation therapy (ADT), there is a growing need for more effective and personalized treatment options. The success of androgen receptor inhibitors, such as Enzalutamide (Xtandi) and Apalutamide (Erleada), in delaying metastasis and improving survival rates has created a significant demand for such therapies.

Additionally, the rising awareness of prostate cancer, coupled with advancements in early diagnostic methods like PSA testing and multiparametric MRI, has led to earlier detection of non-metastatic prostate cancer. This early detection allows for timely intervention with innovative therapies, which are contributing to the growing demand for treatment options. Moreover, the increasing adoption of precision medicine, based on genetic testing and biomarkers, is enabling more personalized treatments that are tailored to the specific needs of each patient, further accelerating Non-metastatic prostate cancer market growth.

Overall, the demand for more advanced, less toxic, and more effective treatments for non-metastatic prostate cancer, along with early detection and increased awareness, is driving the expansion of the non-metastatic prostate cancer market.

Despite the growth of the Non-metastatic Prostate Cancer market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of advanced therapies. Treatments such as androgen receptor inhibitors (e.g., Enzalutamide and Apalutamide) and newer therapies like immunotherapies or targeted treatments can be extremely expensive, making them less accessible for many patients, especially those without comprehensive insurance coverage. This high cost can also place a significant burden on healthcare systems, limiting widespread adoption, particularly in developing countries or regions with limited access to advanced medical care.

In addition to the cost barrier, another major challenge is treatment resistance. While therapies like Enzalutamide and Apalutamide have shown effectiveness in non-metastatic castration-resistant prostate cancer (nmCRPC), patients may eventually develop resistance to these treatments over time. This can lead to disease progression, forcing physicians to seek alternative therapies or more aggressive interventions, which may not always be available or as effective. The development of castration-resistant prostate cancer despite ongoing androgen deprivation therapy remains one of the most significant hurdles in the long-term management of prostate cancer.

Furthermore, there are limitations in diagnostic tools. Despite advances in imaging technologies like multiparametric MRI and genetic testing, early-stage prostate cancer is still difficult to detect in some cases. PSA testing, while widely used, has limitations in specificity, leading to false positives and false negatives, which can cause delays in accurate diagnosis and treatment planning.

Finally, side effects of current treatments, especially androgen deprivation therapy and chemotherapy, continue to affect patient quality of life. Issues like fatigue, sexual dysfunction, osteoporosis, and cardiovascular risks can make long-term adherence to treatment challenging for many patients, further complicating the management of non-metastatic prostate cancer.

Together, these factors present significant challenges in the Non-metastatic Prostate Cancer market, requiring continued innovation in both treatment options and diagnostic tools to overcome these barriers and improve patient outcomes.

The global Non-metastatic Prostate Cancer market is highly competitive, with several leading companies driving innovation and market growth, such as Johnson & Johnson (Janssen Pharmaceuticals), Astellas Pharma, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Bayer, Sanofi, Clovis Oncology, AstraZeneca, AbbVie, and Boehringer Ingelheim.

These companies are at the forefront of developing and commercializing treatments for non-metastatic prostate cancer, particularly non-metastatic castration-resistant prostate cancer (nmCRPC). Through next-generation androgen receptor inhibitors like Erleada (apalutamide) and Xtandi (enzalutamide), as well as androgen deprivation therapies and PARP inhibitors, they are offering innovative solutions to slow disease progression, delay metastasis, and improve survival rates.

With increased research investments and advancements in precision medicine, these companies are exploring new biomarkers, novel treatment combinations, and immunotherapies to provide more effective therapies tailored to individual patient needs. As global awareness and screening rates for prostate cancer rise, these companies continue to shape the landscape of non-metastatic prostate cancer treatment and contribute to the non-metastatic prostate cancer market's rapid growth.

Non-Metastatic Prostate Cancer Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Non-metastatic Prostate Cancer market is undergoing significant transformation, fueled by emerging trends that are reshaping the landscape of prostate cancer treatment. One of the key trends is the growing focus on precision medicine, where advancements in genomic testing and biomarker profiling are allowing healthcare providers to tailor treatments based on the specific genetic makeup of a patient's cancer.

This approach is leading to the development of targeted therapies, such as Enzalutamide (Xtandi) and Apalutamide (Erleada), which are more effective, and less toxic compared to traditional therapies. In addition, the use of combination therapies is becoming more prevalent, as treatments like androgen receptor inhibitors are being combined with chemotherapy, immunotherapy, and radiation therapy to enhance effectiveness and address resistance.

Furthermore, the continued advancements in diagnostic technologies, such as multiparametric MRI and liquid biopsy, are enabling earlier and more accurate detection of non-metastatic prostate cancer, allowing for timely intervention. As global awareness of prostate cancer increases and screening programs become more widespread, more men are being diagnosed at earlier stages, driving demand for innovative therapies. Together, these trends are not only transforming how non-metastatic prostate cancer is treated but also expanding the non-metastatic prostate cancer market and improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Non-metastatic Prostate Cancer Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Non-metastatic Prostate Cancer Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Non-metastatic Prostate Cancer Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Non-metastatic Prostate Cancer Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Non-metastatic Prostate Cancer Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Non-metastatic Prostate Cancer Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Johnson & Johnson (Janssen Pharmaceuticals)
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Astellas Pharma
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Bristol-Myers Squibb
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Pfizer Inc.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Merck & Co.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Bayer AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Sanofi
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Clovis Oncology
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 AstraZeneca
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 AbbVie Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Non-metastatic Prostate Cancer Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Non-metastatic Prostate Cancer Market Key Trends, Analysis

List of Tables

  • Table: Global Non-metastatic Prostate Cancer Market Dynamics, Impact Analysis
  • Table: Global Non-metastatic Prostate Cancer Market (by Region), $Billion, 2024-2035